权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel Pharmaceutical Solvent-Water Separation System

新型制药溶剂-水分离系统

基本信息

批准号：
7497578
负责人：
Stuart Nemser
金额：
$ 45.45万
依托单位：
COMPACT MEMBRANE SYSTEMS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-04-01 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7497578
关键词：
Air Alcohols Amines Area Biological Biological Models Biomass Capital Chemical Industry Chemicals Commit Compatible Condition Data Dehydration Drug Industry Economics Environment Esters Ethanol Evaluation Family Fiber Flame Retardants Gasoline Industry Isopropanol Ketones Lead Liquid substance Marketing Medal Membrane Methanol Names Nature Numbers Oils Operating System Operative Surgical Procedures Organic solvent product Oxygen Performance Permeability Pharmacologic Substance Phase Polytetrafluoroethylene Polyvinyl Alcohol Process Range Rate Recovery Relative (related person)Research Personnel Resistance Resources Route Savings Side Silicon Dioxide Site Solvents Structure System Technology Temperature Testing Today Water Work base chemical reaction chemical stability commercialization concept cost cost effective design engineering design improved innovation interest novel organic acid polyvinylidene fluoride programs vapor

项目摘要

DESCRIPTION (provided by applicant): In Phase I we exceeded all key objectives. We demonstrated in both pervaporation and vapor separation the combination of high membrane permeation and high membrane separation when evaluating isopropyl alcohol (IPA)-Water separation. Membrane stability, which had been concern of reviewers, was shown to be excellent and far superior to other commercial membranes. CMS membranes were shown to be stable up to 130¿C and over the whole compositional operating range. Economic evaluations showed the CMS membranes to have in excess of 80% capital savings compared to existing drying processes. In addition to work on IPA-water, two other pharmaceutical solvents were successfully evaluated. Leaching studies have shown the CMS membranes to be stable. Based on results and commercialization analysis the CMS system is seen as a platform technology. Significant opportunities exist in pharmaceutical solvent recovery enhancing chemical reactions, chemical industry solvent recovery, manufacture of fuel grade ethanol and stabilizing industrial esters. With many opportunities, a large number of industrial and pharmaceutical companies as well as leading researchers have committed to actively participate in this program. This participation will enhance overall chances for commercialization. In Phase II we will first fabricate high flux composite membrane modules. Then we would focus our demonstration on IPA-water systems operating in pervaporation (PV) mode. Focus will be on PV since this is the simplest system for the end user. Once successful basic data on IPA-water in PV is obtained we will expand the evaluation to other pharmaceutical solvents and also evaluating membranes in the vapor separation mode. Additional upgrades will include modeling and system design to enhance overall purification; long term testing plus extended solvent leaching tests; develop enhanced membrane modules using commercial hollow fiber supports; building large skid for field testing and expanding our economic evaluation to show superior performance to alternative drying routes. Throughout this Phase II we will work closely with our industrial partners. This program develops a low cost, simple, process to recover pharmaceutical solvents. This will encourage solvent reuse which is environmentally attractive and cost effective. The process will also keep potential biological contaminants out of the environment.

描述（由申请人提供）：在第一阶段，我们超过了所有关键目标。我们在评价异丙醇（IPA）-水分离时，在渗透蒸发和蒸汽分离中证明了高膜渗透和高膜分离的组合。膜的稳定性，这一直是评论家关注的，被证明是优秀的，远远优于其他商业膜上级。CMS膜在高达130 ℃和整个组成操作范围内显示出稳定性。经济评估表明，与现有的干燥工艺相比，CMS膜具有超过80%的资本节省。除了对IPA-水的研究外，还成功评价了另外两种药用溶剂。沥滤研究表明CMS膜是稳定的。基于结果和商业化分析，CMS系统被视为一个平台技术。重要的机会存在于制药溶剂回收增强化学反应，化学工业溶剂回收，燃料级乙醇的制造和稳定工业酯。有了很多机会，大量的工业和制药公司以及领先的研究人员都致力于积极参与这一计划。这种参与将增加商业化的整体机会。在第二阶段，我们将首先制造高通量复合膜组件。然后，我们将集中我们的示范在渗透蒸发（PV）模式下运行的IPA-水系统。重点将放在PV上，因为这是最终用户最简单的系统。一旦成功获得PV中IPA-水的基本数据，我们将扩展评估到其他药物溶剂，并在蒸汽分离模式下评估膜。其他升级将包括建模和系统设计，以提高整体净化;长期测试加上延长溶剂浸出测试;开发使用商业中空纤维支撑的增强膜组件;建造大型滑道进行现场测试，并扩大我们的经济评估，以显示替代干燥路线的上级性能。在第二阶段，我们将与我们的工业伙伴密切合作。该计划开发了一种低成本，简单的工艺来回收制药溶剂。这将鼓励溶剂再利用，这对环境有吸引力且具有成本效益。该过程还将使潜在的生物污染物远离环境。